91% Accuracy of New Blood Test for Chronic Fatigue Syndrome

For years, Chronic Fatigue Syndrome (CFS) can be misdiagnosed, depriving sufferers of the critical medical care they require. Surprisingly, up to 91% of people in the US live with this ailment unofficially diagnosed, leading to lives depleted of vitality, energy, and mental clarity. There is, however, fresh optimism because a ground-breaking diagnostic technique has been developed.

An elite group of researchers led by the University of Oxford have released preliminary research on a state-of-the-art blood cell-based test that can distinguish between healthy people and those suffering from CFS, also known as Myalgic Encephalomyelitis or ME/CFS, with an astounding 91% accuracy rate.

Jiabao Xu and colleagues’ ground-breaking open-access, peer-reviewed paper team emphasizes the critical importance of an inexpensive, effective diagnostic method for ME/CFS. They contend that particularly if this blood test can follow changes over time, early diagnosis can enable individuals to control their health more effectively and may potentially open the door for ground-breaking discoveries in disease pathways and cutting-edge treatment choices.

Modern Technology in Use:

This ground-breaking blood test works by identifying the distinctive features of peripheral blood mononuclear cells (PBMCs), a particular type of blood cell, in people with and without ME/CFS. It makes use of cutting-edge Raman spectroscopy technology and technologies from artificial intelligence (AI).

Previous studies have suggested that people with ME/CFS have PBMCs with lower energy function, which is consistent with the growing theory that impaired energy generation is the primary cause of this disease.

Xu and his colleagues meticulously tested their diagnostic methodology on nearly 100 people, including 61 ME/CFS patients, 16 healthy controls, and 21 people suffering from multiple sclerosis, an autoimmune disorder that shares many symptoms with ME/CFS, as part of an expanded study that took into account the evidence suggesting PBMC perturbations in ME/CFS.

A Bright Future:

The blood test methodically profiled almost 2,000 cells from 98 patient samples, paying close attention to each cell’s molecular vibrations. The obtained spectra revealed variations in intracellular metabolite levels produced during cellular fuel metabolism, similar to those used in astronomy to examine the chemical makeup of stars.

Amazingly, this ground-breaking test showed an amazing 91% accuracy rate in differentiating between patients using the AI system. could even distinguish with an accuracy rate of 84% between mild, moderate, and severe ME/CFS cases.

While additional validation in larger study cohorts is still in the works, Xu and his team are optimistic that their approach will solve the sample processing problems that other research teams have run across. It’s vital to remember that not all accredited diagnostic laboratories have access to single-cell Raman spectroscopy yet.

Increasing Promise:

Notably, comparable blood-cell-based diagnostics using various analytical methods have previously shown considerable potential. Since then, however, there have been no further developments. (It’s important to note that the Stanford team’s research into ME/CFS is ongoing.)

The majority of ME/CFS patients long for easy access to effective treatment options while they wait for a diagnosis.

Dispute Your Doubts:

According to Xu and colleagues, a sizable segment of the medical profession continues to harbor reservations about ME/CFS, leaving patients with few treatment options and a hazy understanding of the biology of the condition.

We sincerely hope that groundbreaking studies, such as this one that identifies quantifiable biochemical changes in this severely disabling disorder, will usher in a new era of innovation in ME/CFS diagnosis and treatment.